Disrupting the 20 billion antidepressant market Xinlitai's blockbuster drug stabilized?

Author: Clover

Recently, Xinlitai issued a corporate announcement stating that the application for clinical trials of the innovative drug SAL0114 tablets independently developed by its company and intended to be used for severe depression has been accepted by the National Medical Products Administration

Is the chance of following the AXS-05 medicine stable?

According to the inquiry of Yaozhi Patent Tong, SAL0114 tablet is a pharmaceutical composition containing duloxetine.

Due to its patent protection, more information about the SAL0114 film is not yet known, but careful netizens have found that the target of the SAL0114 film may follow is the AXS-05 of a listed company AXSM in the United States

AXS-05 is a new type of oral N-methyl-D-aspartate (NMDA) receptor antagonist used to treat depression and other central nervous system (CNS) diseases

Dextromethorphan is a non-competitive NMDA receptor antagonist with antitussive effect.

It is worth noting that AXS-05 received a breakthrough therapy in 2019, and NDA was given priority review by the FDA in 2020, which once caused AXSM's stock price to soar

According to public data, there are currently more than 350 million depression patients in the world, and China accounts for more than a quarter of the total number of patients, and the growth rate is very fast.

It is also worth mentioning that clinical antidepressants have undergone several generations of updates.

Therefore, Xinlitai SAL0114 tablet is developed following AXS-05, and it is very likely to become a better follow drug, and the probability of being a drug is greatly improved.

"Sell, sell, sell," and "buy, buy, buy," aggressively attack innovative drugs, will "bottom out"?

Returning to the Xinlitai company itself, in recent years, Xinlitai has suffered serious setbacks, but it has maintained intensive cultivation of chronic disease drugs, continued to innovate and research and developed, and has successfully transformed into an innovative drug company

As we all know, Xinlitai originated from "Taijia", a chronic cardiovascular drug.

To this end, Xinlitai has launched various "sell-off-sell" models to withdraw funds while slimming down generic drugs

While increasing the layout of innovative research and development, "buy, buy and buy", aggressively attack innovative drugs

Xinlitai's main research drug projects and clinical progress

Data source: Semi-annual report, compiled by Yaozhi.

Innovative R&D pipelines are abundant, and R&D is inseparable from R&D investment.

Overview of Xinlitai R&D investment over the years

Image source: Yaozhi Data

Nowadays, a blockbuster drug SAL0114 with a high probability of being a drug has been approved for clinical application, and with its rich R&D pipeline layout, Xinlitai may be an underestimated silent farmer.

references:

1.
The era of medicine: Biotech, a star whose stock price has doubled 40 times in one year, has now fallen back to its blockbuster drug after being sent a letter by the FDA.
.
.

2.
Snowball TOPCP column: SAL0114: a drug with a high probability of being delivered

3.
Public information such as corporate announcements